Balversa (erdafitinib) — United Healthcare
Invasive breast cancer
Initial criteria
- Diagnosis of invasive breast cancer
- Disease is metastatic
- Presence of FGFR1-3 genetic alterations
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Balversa therapy
Approval duration
12 months